Making sure patients receive the value added by an orphan drug

In Uncategorized by Matt Turner

Carlo IncertiThe tightening of healthcare budgets throughout Europe has led to a growing concern surrounding the premium prices of orphan drugs.

With a balance needed to ensure investors see return whilst payers stay on budget, it is paramount that patients remain the number one concern. The World Orphan Drug Congress 2011 will stage an open debate for all stakeholders involved in pricing, reimbursement and market access.

Carlo Incerti, Senior VP Global Market Access at Genzyme will take to the stage and deliver expert strategic knowledge of how to guarantee your orphan drug reaches the patients in need. With small patient populations, discover how to obtain the clinical data necessary for approval and how to undertake post-approval studies to confirm efficacy and ensure reimbursement.

Download the brochure to see the full agenda and speaker line up and register before 22nd July to receive our largest discount!